RGNX earnings analysis
What we found in RGNX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
REGENXBIO's Q1 2026 results showed a significant decline in revenues, falling to $6.4 million compared to $89 million in the same quarter the previous year, largely due to a substantial decrease in license and royalty revenues. The company reported a net loss of $90.1 million for the quarter, significantly worsening from the net income of $6.1 million a year earlier, alongside cash flow challenges as operating activities consumed $76.2 million, up from positive cash flow in the prior year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Dramatic Revenue Decline
- Q1 revenues plunged to $6.4 million, down from $89 million year-over-year.
- Increased EPS Loss
- Reported EPS loss of -$1.72 compared to a gain of $0.12 in Q1 2025.
- Research & Development Investment Continues
- R&D expenses rose to $57.3 million from $53.1 million in Q1 2025.
- Cash and Cash Equivalents at $150.5M
- As of March 31, 2026, the company held $150.5 million in cash and cash equivalents.
- Operational Cash Flow Loss
- Net cash used in operating activities was $76.2 million, a stark contrast to a positive cash flow of $33.6 million in Q1 2025.
- Significant Increase in Operating Expenses
- Total operating expenses rose to $89.8 million, compared to $76.9 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Sharp Revenue Decline
- License and royalty revenue fell by $82 million, significantly impacting financial stability.
- High Net Loss
- Net loss of $90.1 million compared to a net income of $6.1 million in Q1 2025.
- Cash Burn Rate Increase
- Operating expenses increased to $89.8 million, raising concern over cash runway.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.72
What they said about what is next.
Liquidity outlook indicates current cash, cash equivalents, and securities will sustain operations into early 2027.
The filing reads worse than the one before it.
What came before.
- 10-K · March 5, 2026
- REGENXBIO Inc. faced a challenging year ending December 31, 2025, with substantial financial losses and regulatory hurdles impacting key programs. Despite notable revenues from license agreements, the company reported a…
- 10-Q · November 6, 2025
- REGENXBIO Inc. reported significant revenue growth in Q3 2025, achieving $29.73 million, a 23.7% increase from the prior quarter's $24.19 million and up 11.1% year-over-year. Although the company continues to face…
- 10-Q · August 7, 2025
- REGENXBIO reported disappointing Q2 2025 results with a revenue of $21 million, down 6% from the previous quarter and significantly below estimates. The net loss increased to $70.9 million as operating expenses grew,…
- 10-Q · May 12, 2025
- RGNX reported strong revenue growth in Q1 2025, with total revenues increasing to $89M driven by significant licensing revenue from new collaborations. However, the company posted lower-than-expected diluted EPS of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RGNX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever